Release
FDA approves first factor XIa inhibitor for secondary stroke prevention
The Brief
- The FDA approved Sunharbo (asundexian) 50 mg tablets, taken with antiplatelet therapy, to reduce stroke risk in adults.
- The approval covers adults after a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack.
- Asundexian is described as the first factor XIa inhibitor approved by the FDA for secondary stroke prevention.
Why it matters
It adds a new anticoagulant-class drug targeting factor XIa for preventing a second stroke, a population with high recurrence risk, giving clinicians a new option alongside antiplatelet therapy.
Who’s affected
- clinicians treating stroke and transient ischemic attack patients
- patients with recent noncardioembolic ischemic stroke or high-risk TIA
- pharmaceutical and regulatory professionals
- #stroke prevention
- #factor xia inhibitor
- #asundexian
- #fda approval
- #anticoagulation
The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack…